PellePharm today announced that the company is scheduled to participate in the Cantor Fitzgerald Dermatology and Aesthetics Summit.
PellePharm, a late clinical-stage biopharmaceutical company committed to targeting rare dermatologic conditions at their source, today announced that the company is scheduled to participate in the Cantor Fitzgerald Dermatology and Aesthetics Summit, Tuesday, June 19, at 2:00 p.m. ET at the Westin Grand Central Hotel in New York, New York.
About PellePharm
Founded by world leaders in hedgehog pathway signaling, PellePharm is a biotechnology company committed to targeting hedgehog-driven diseases, including Gorlin Syndrome and Basal Cell Carcinomas (BCCs), at their source. PellePharm’s mission is to improve the quality of life for those suffering from Gorlin Syndrome and BCCs by providing an easy-to-use topical solution that eliminates the need for regular, painful surgeries. Topical patidegib is a first-in-class topical gel formulation of a proprietary hedgehog inhibitor.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180613005200/en/
View this news release online at:
http://www.businesswire.com/news/home/20180613005200/en
